Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats

Hepatology

Volumn 48, Issue 6, 2008, Pages 1864-1873

  Altomonte, Jennifer ^a   Braren, Rickmer ^a   Schulz, Stephan ^a   Marozin, Sabrina ^a   Rummeny, Ernst J ^a   Schmid, Roland M ^a   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CONTRAST MEDIUM; ONCOLYTIC VIRUS; STARCH MICROSPHERE; MICROSPHERE; STARCH;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MONOTHERAPY; MULTIPLE CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; ANIMAL; APOPTOSIS; BUFFALO RAT; DISEASE MODEL; GENETICS; HEPATIC ARTERY; LIVER TUMOR; MALE; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; LIVER NEOPLASMS; MALE; MICROSPHERES; ONCOLYTIC VIROTHERAPY; RATS; RATS, INBRED BUF; STARCH; VESICULOVIRUS;

EID: 58149390233     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22546     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J., Pisani, P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. Befeler A, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
4. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353: 1253-1257.
5. Llovet J, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
6. Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer. Lancet 1998;351:214-215.
7. Taylor-Robinson S, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK. Lancet 1997;350:1142-1143.
8. Llovet J, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. HEPATOLOGY 1999;39:1434-1440.
9. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018-1022.
10. Yao F, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883.
11. Blum H. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005;11:7391-7400.
12. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188.
13. Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, et al. Efficacy of transcatheter embolization/chemoembolization (TAE/ TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 2007;13:2952-2955.
14. Lein W, Ackerman NB. The blood supply of experimental liver metastases. Surgery 1970;68:334-340.
15. Anderson J, Gianturco C, Wallace S. Experimental transcatheter intraarterial infusion-occlusion chemotherapy. Invest Radiol 1981;16:496-500.
16. Tancredi T, McCuskey PA, Kan Z, Wallace S. Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Radiology 1999;211:177-181.
17. Llovet J, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003;37:429-442.
18. Chang J, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma: a randomized controlled study. Cancer 1994;74:2449-2453.
19. Bruix J, Llovet JM, Castells A, Montaua X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized controlled trial in a single institution. HEPATOLOGY 1998;27:1578-1583.
20. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege M, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998;29:129-134.
21. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224: 47-54.
22. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management, and future directions. Nat Med 2001;7:781-787.
23. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Research 1994;54: 6017-6021.
24. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98:2002-2007.
25. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell, JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-825.
26. Rose JK, Whitt MA. Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1221-1242.
27. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SLC. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003;63: 611-613.
28. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL, et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004;64:3265-3270.
29. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 2004;9:368-376.
30. Shinozaki K, Ebert O, Woo SL. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. HEPATOLOGY 2005;41:196-203.
31. Erichsen C, Bolmsjo M, Hugander A, Jonsson PE. Blockage of the hepatic-artery blood flow by biodegradable microspheres (Spherex) combined with local hyperthermia in the treatment of experimental liver tumors in rats. Clin Oncol 1985;109:38-41.
32. Wang J, Murata S, Kumazaki T. Liver microcirculation after hepatic artery embolization with degradable starch microspheres. World J Gastroenterol 2006;12:4214-4218.
33. Yoshikawa T, Kokura S, Oyamada H, Iinuma S, Nishimura S, Kaneko T, et al. Antitumor effect of ischemia-reperfusion injury induced by transient embolization. Cancer Res 1994;54:5033-5035.
34. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001;75: 3474-3479.
35. Kopecky SA, Willingham MC, Lyles DS. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 2001;75:12169-12181.
36. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15:1686-1693.
37. Zhang H, Wen YJ, Mao BY, Gong QY, Qian ZY, Wei YQ. Plasmid encoding matrix protein of vesicular stomatitis viruses as an antitumor agent inhibiting rat glioma growth in situ. Exp Oncol 2007;29:85-93.
38. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006;41:516-521.
39. Altomonte J, Wu L, Chen L, Meseck M, Ebert O, Garcia-Sastre A, et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008;16:146-153.
40. Welsh RM. Regulation of virus infections by natural killer cells. Nat Immun Cell Growth Reg 1986;5:169-199.
41. Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y, Kitahara M, Arai K, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007;147:296-305.
42. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-807.
43. Diaz R, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007;67:2840-2848.
44. Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res 2006;66:960-969.
45. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 38:1734-1739.
46. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2006;30:6-25.
47. Petraccia L, Onori P, Sferra R, Lucchetta MC, Liberati G, Grassi M, et al. MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications. Clin Ter 2003;154:325-335.
48. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001;94:492-499.
49. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1178-1182.
50. Connor JH, Naczki, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 2004;78:8960-8970.